Sigachi Industries Share Price
18 Aug, 2026 1:07 PM (IST)
Sigachi Industries Performance
- Today's Low
- ₹26
- Today's High
- ₹30
- 52 Week Low
- ₹17
- 52 Week High
- ₹47
- Open Price₹26
- Previous Close₹26
- Volume6,261,059
- 50 DMA₹24.60
- 100 DMA₹24.10
- 200 DMA₹26.60
Sigachi Industries Chart
Investment Returns
- Over 1 Month + 16.79%
- Over 3 Month + 44.3%
- Over 6 Month + 26.6%
- Over 1 Year -4.73%
Smart Investing Starts Here Start SIP with Sigachi Industries for Steady Growth!
Sigachi Industries Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 44
- PEG Ratio
- 0.3
- Market Cap Cr
- 1,117
- P/B Ratio
- 2.1
- Average True Range
- 1
- EPS
- 0.7
- Dividend Yield
- 0.3
- MACD Signal
- 0.7
- RSI
- 55.7
- MFI
- 61.36
Latest Stock News Updates
<h3><span style="font-size:16px;"><strong>Pharmaceuticals company Sigachi Industries announced Q1FY27 results</strong></span></h3> <p _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Consolidated Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c1940132427="">Revenue from Operations for Q1FY27 stood at Rs 12,127.38 lakh, reflecting a decrease of 5.44% from Rs 12,824.62 lakh in Q1FY26 and a marginal decline of 0.51% from Rs 12,189.51 lakh in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">Total Income reached Rs 12,227.67 lakh in Q1FY27, representing a YoY decline of 7.50% compared to Rs 13,218.94 lakh in Q1FY26 and a 0.78% decrease from Rs 12,324.22 lakh in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">Profit before tax (PBT) was Rs 1,008.97 lakh in Q1FY27, a significant turnaround compared to a loss of Rs 10,099.29 lakh in Q1FY26. On a QoQ basis, PBT increased by 30.82% from Rs 771.29 lakh in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">Profit for the period (PAT) was Rs 814.47 lakh in Q1FY27, compared to a loss of Rs 10,097.08 lakh in Q1FY26. PAT grew by 6.49% on a QoQ basis from Rs 764.81 lakh in Q4FY26.</li> </ul> <p><strong _ngcontent-ng-c1940132427="">Standalone Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c1940132427="">Revenue from Operations for Q1FY27 was Rs 9,827.58 lakh, down 11.45% YoY from Rs 11,097.65 lakh in Q1FY26 and up 6.71% QoQ compared to Rs 9,209.51 lakh in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">Total Income stood at Rs 9,871.92 lakh in Q1FY27, a YoY decrease of 14.10% from Rs 11,491.74 lakh in Q1FY26 and a 5.67% increase over Rs 9,342.22 lakh in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">Profit for the period (PAT) reached Rs 650.67 lakh in Q1FY27, compared to a loss of Rs 9,914.49 lakh in Q1FY26. PAT rose by 32.65% QoQ from Rs 490.50 lakh in Q4FY26.</li> </ul> <p><strong _ngcontent-ng-c1940132427="">Business Highlights:</strong></p> <ul> <li _ngcontent-ng-c1940132427="">Consolidated Segment Revenue: <ul> <li _ngcontent-ng-c1940132427="">Pharmaceuticals: Rs 10,821.40 lakh in Q1FY27.</li> <li _ngcontent-ng-c1940132427="">Operational and Management: Rs 1,305.97 lakh in Q1FY27.</li> </ul> </li> <li _ngcontent-ng-c1940132427="">Consolidated Segment Results (Profit before tax and interest): <ul> <li _ngcontent-ng-c1940132427="">Pharmaceuticals: Rs 1,081.67 lakh in Q1FY27.</li> <li _ngcontent-ng-c1940132427="">Operational and Management: Rs 228.61 lakh in Q1FY27.</li> </ul> </li> <li _ngcontent-ng-c1940132427="">Standalone Segment Revenue: <ul> <li _ngcontent-ng-c1940132427="">Pharmaceuticals: Rs 8,521.61 lakh in Q1FY27.</li> <li _ngcontent-ng-c1940132427="">Operational and Management: Rs 1,305.97 lakh in Q1FY27.</li> </ul> </li> <li _ngcontent-ng-c1940132427="">Standalone Segment Results (Profit before tax and interest): <ul> <li _ngcontent-ng-c1940132427="">Pharmaceuticals: Rs 769.35 lakh in Q1FY27.</li> <li _ngcontent-ng-c1940132427="">Operational and Management: Rs 228.61 lakh in Q1FY27.</li> </ul> </li> <li _ngcontent-ng-c1940132427="">Forfeiture of Warrants: The company approved the forfeiture of 3,50,57,990 convertible warrants as the conversion option was not exercised within the 18-month tenure ending February 09, 2025. Consequently, the 25% upfront consideration amounting to Rs 22,87,53,813 has been forfeited.</li> <li _ngcontent-ng-c1940132427="">IPO Proceeds Utilization: Funds allocated for MCC production capacity expansion at Dahej (Rs 2,815.82 lakh) and Jhagadia (Rs 2,924.13 lakh) were fully utilized by Q4FY23. A remaining unutilized balance of Rs 3,229.87 lakh is available for the CCS project at Dahej.</li> <li _ngcontent-ng-c1940132427="">Board Appointments: Ms. Dhanalakshmi Guntaka and Mr. Janardhana Reddy Yeddula were re-appointed as Independent Directors for a second five-year term, effective from October 18, 2026, and November 30, 2026, respectively.</li> </ul> <p><a class="lb" href="/get-document/post/pdf/5788047/" target="_blank">Result PDF</a></p>
- Trendlyne
- 4 days ago
Newspaper Publication
- BSE India
- 4 days 1 hour ago
Monitoring Agency Report for the quarter ended June 30, 2026
- BSE India
- 4 days 18 hours ago
Sigachi Industries Financials
Sigachi Industries Technicals
EMA & SMA
- Bearish Moving Average 0
- Bullish Moving Average 16
- 20 Day
- ₹25.90
- 50 Day
- ₹24.60
- 100 Day
- ₹24.10
- 200 Day
- ₹26.60
Resistance and Support
- R3 29.80
- R2 28.90
- R1 27.60
- S1 25.40
- S2 24.50
- S3 23.20
Sigachi Industries Corporate Actions - Bonus, Splits, Dividends
About Sigachi Industries
Sigachi Industries Ltd. is leading manufacturer of microcrystalline cellulose (MCC), key excipient used in pharmaceutical, food, & cosmetic industries. Founded in 1989, Sigachi has established itself as reliable supplier of high quality MCC, with strong presence in both domestic & international markets. company operates multiple manufacturing facilities across India, equipped with advanced technology & adhering to stringent quality standards. Sigachi's commitment to research & development has enabled it to innovate & expand its product portfolio, catering to wide range of applications. company's focus on sustainability & customer satisfaction has earned it strong reputation in industry.
SIL has established three multi-locational manufacturing units in Jhagadia, Dahej, & Hyderabad with goal of strategically expanding operations & ensuring market presence in both domestic & international markets. This enables SIL to provide timely, efficient, & customized product delivery in terms of particular demographic needs. As of March 31, 2023, SIL had three plants spread across Gujarat & Telangana with aggregate installed capacity of 13,950 MTPA. After expansion at Dahej & Jhagadia is completed, that capacity is anticipated to rise to 21,000 MTPA. buildings are equipped with systems & equipment that meet World Health Organization (WHO-GMP) & United States Food & Drug Association (USFDA) standards.
View More- NSE Symbol
- SIGACHI
- BSE Symbol
- 543389
- Managing Director,Chief Executive Officer
- Amit Raj Sinha
- ISIN
- INE0D0K01022
Similar Stocks to Sigachi Industries
Popular Stocks
Sigachi Industries FAQs
Sigachi Industries share price is ₹29 As on 18 August, 2026 | 12:53
The Market Cap of Sigachi Industries is ₹1116.5 Cr As on 18 August, 2026 | 12:53
The P/E ratio of Sigachi Industries is 44 As on 18 August, 2026 | 12:53
The PB ratio of Sigachi Industries is 2.1 As on 18 August, 2026 | 12:53
The 52 week High & Low of Sigachi Industries is ₹46.7/₹16.6 respectively As on 18 August, 2026 | 12:53
Evaluate company's market position in excipient industry & its financial performance before investing.
Key metrics include revenue growth, export performance, & profit margins.
Open Demat account with 5 Paisa Capital & post doing KYC & active account search for Sigachi Industries share, you can then put order as you prefer.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.